Copyright
©The Author(s) 2020.
World J Gastroenterol. Apr 28, 2020; 26(16): 1888-1900
Published online Apr 28, 2020. doi: 10.3748/wjg.v26.i16.1888
Published online Apr 28, 2020. doi: 10.3748/wjg.v26.i16.1888
Table 3 Scheme dose, adverse events and discontinuation rate of first and second line tyrosine kinase inhibitors and anti-vascular-endothelial growth factor agents approved for the treatment of advanced hepatocellular carcinoma
Study drug | Dose reduction - interruption | Discontinuation rate |
Sorafenib | 26% dose reduction (any AE), 44% drug interruption (any AE), most frequent AE leading to dose reductions: diarrhea, hand-foot skin reaction and rash | 11% |
Lenvatinib | 37% dose reduction (related-AE), 40% drug interruption (related-AE), Most frequent AE leading to dose reductions: not reported | 9% |
Regorafenib | 68% dose reduction or drug interruption (any AE), most frequent AE leading to dose reductions: diarrhea, hand-foot skin reaction | 10% |
Cabozantinib | 62% dose reduction or drug interruption (any AE), most frequent AE leading to dose reductions: diarrhea, hand-foot skin reaction | 16% |
Ramucirumab | 34% dose reduction or drug interruption (any AE), most frequent AE leading to dose reductions: fatigue, peripheral edema, hypertension and anorexia | 11% |
- Citation: Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900
- URL: https://www.wjgnet.com/1007-9327/full/v26/i16/1888.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i16.1888